Reports Q1 revenue $64.18M, consensus $60.55M. “We had a solid start to the year, and I am proud of the drive and intensity from our strengthened commercial team, which delivered additional wins and expanded relationships among biotech, biopharma, CDMO, and academic customers,” said Trey Martin, Chief Executive Officer of Maravai. “We are executing on our return to growth strategy, bringing new innovations, and increased manufacturing capacity to our customers, moving us closer to our goal of long-term sustainable growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai Lifesciences subsidiary, Lonza enter license and supply pact for capping
- Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
- Craig-Hallum bullish on Maravai Lifesciences, initiates with a Buy
- Maravai Lifesciences initiated with a Buy at Craig-Hallum
- Applied DNA Sciences enters manufacturing agreement with Alphazyme